ITSC for Leukemia: Novel Molecular Strategies for NCTN: "Individualized" Therapie

ITSC​​ 治疗白血病：NCTN 的新型分子策略：“个体化”治疗

• 批准号: 9256443
• 负责人: CLARA D BLOOMFIELD
• 金额: $ 64.39万
• 依托单位: OHIO STATE UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-05-02 至 2019-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9256443
• 关键词: Adopted; Adult; Area; Biological Markers; Cancer Biology; Center for Translational Science Activities; Clinical; Clinical Trials; Creativeness; Data; Development; Disease; Enrollment; Funding; Genetic; Genetic Markers; Goals; Individual; Institutes; International; Malignant Neoplasms; Molecular; Molecular Abnormality; Molecular Profiling; National Cancer Institute; National Clinical Trials Network; Outcome; Patient-Focused Outcomes; Patients; Pharmacologic Substance; Phase; Pilot Projects; Prognostic Marker; Protocols documentation; Reproduction spores; Research; Research Personnel; Science; Southwest Oncology Group; Stratification; System; Technology; Therapeutic; Therapeutic Trials; Tissues; United States; Work; adult leukemia; cancer clinical trial; cancer type; clinical translation; clinically relevant; design; epigenetic marker; genetic predictors; high throughput technology; improved; individualized medicine; innovation; leukemia; molecular diagnostics; molecular subtypes; new technology; novel; oncology; planetary Atmosphere; programs; public health relevance; targeted treatment; therapeutic target; therapy resistant; translational medicine; treatment response; tumor

DESCRIPTION (provided by applicant): Advances in understanding the molecular basis of leukemia, together with the wealth of emerging innovative pharmaceutical compounds, have brought great opportunities to improve the clinical outcome of patients. To maximize the value of these discoveries, it is imperative to demonstrate our ability to molecularly characterizing individual tumors and apply this information to enroll patients onto therapeutic protocols that match distinct molecular profiles to specific targeting treatments-all within the context of an effective cancer therapeutic trials' system. To create an atmosphere for both research creativity and rapid clinical translation of novel discoveries into treatment approaches of adult leukemia patients, the Alliance for Clinical Trials in Oncology (hereafter called Alliance) Leukemia Correlative Science Committee (A-LCSC), the SWOG Leukemia Translational Medicine Subcommittee (S-LTMS) and the Broad Institute have elected to join forces and create an Integrated Translational Science Center for Leukemia (ITSC-L). The overall goal of the ITSC-L is to identify the genetic and molecular aberrations that characterize leukemic transformation, understand their contribution to therapeutic response or resistance, and utilize this information for the design of rational therapeutic trials that match specific molecular aberrations to emerging targeted therapies. These goals will be achieved through the carefully selection of Pilot Studies and Collaborative Projects that involve outstanding investigators working within Alliance and SWOG and those working outside the groups. Ultimately, these efforts should not only result in a significant improvement in the clinical outcome for leukemia patients, but are expected to generate cutting-edge findings applicable to other types of cancer. The Specific Aims of this Program are the following: Specific Aim 1. To create an Integrated Translational Science Center for Leukemia (ITSC-L) that will promote research among investigators working within the NCI National Clinical Trials Network (NCTN) system and outside the system by providing and coordinating funding, expertise, technology, tissue and data for innovative studies with clinical relevance; Specific Aim 2. To identify novel prognostic and predictive genetic and epigenetic markers and therapeutic targets for the development of innovative therapeutic paradigms that transform the current approach to leukemia patients and improve their cure rate; Specific Aim 3. To rapidly integrate high impact correlative science into early and late phase therapeutic trials o leukemia supported by the NCTN.

描述（由申请人提供）：了解白血病的分子基础的进步，以及新兴创新的药物化合物的丰富，为改善患者的临床结果带来了巨大的机会。为了最大程度地提高这些发现的价值，必须证明我们有能力表征分子表征个别肿瘤，并将这些信息应用于患者进入治疗方案中，这些方案与有效的癌症治疗试验系统的背景下，将独特的分子特征与特定的靶向治疗相匹配。 To create an atmosphere for both research creativity and rapid clinical translation of novel discoveries into treatment approaches of adult leukemia patients, the Alliance for Clinical Trials in Oncology (hereafter called Alliance) Leukemia Correlative Science Committee (A-LCSC), the SWOG Leukemia Translational Medicine Subcommittee (S-LTMS) and the Broad Institute have elected to join forces and create an Integrated Translational Science Center for Leukemia （ITSC-L）。 ITSC​​-L的总体目标是确定表征白血病转化的遗传和分子畸变，了解其对治疗反应或抗性的贡献，并利用这些信息来设计有理学治疗试验，这些试验匹配特定的分子畸变，以使其与出现的分子差异相匹配 靶向疗法。这些目标将通过精心选择的试点研究和协作项目来实现，这些项目涉及在联盟和摇摆中工作的杰出调查员以及在小组之外工作的研究人员。最终，这些努力不仅应导致白血病患者的临床结局显着改善，而且预计将产生适用于其他类型癌症的尖端发现。该计划的具体目的是：特定目的1。创建一个集成的白血病转化科学中心（ITSC-L），该中心将促进NCI国家临床试验网络（NCTN）系统中工作的研究人员之间的研究以及系统外部的研究，通过提供和协调资金，专业知识，技术，技术，组织和数据的临床相关性，并协调资金，专业知识，技术，组织和数据；具体目的2。确定新的预后和预测性遗传和表观遗传标记以及用于发展创新治疗范式的治疗靶标，这些范例可以改变当前的白血病患者的方法并提高其治愈率；具体目的3。将高影响力相关科学迅速整合到NCTN支持的白血病的早期和晚期治疗试验中。